Business
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47th European Cystic
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47th European Cystic Fibrosis Conference on Thursday, June 6, 2024 at 5:00 p.m. BSTCompany to host webcast on Thursday, June 6, 2024 at 8:00 a.m. ET EMERYVILLE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that interim data from the Phase 1/2 AEROW clinical trial evaluating aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 47th European Cystic Fibrosis Conference, taking place in Glasgow, UK. The Company will host a webcast to discuss the data in detail and provide a program update on Thursday, June 6 at 8:00 a.m. ET. 47th European Cystic Fibrosis Conference Presentation Details: Title:CFTR transgene expression in airway epithelial cells following aerosolized administration of the AAV-based gene therapy 4D-710 to adults with cystic fibrosis lung diseaseSession:WS06 – Where are we with new therapeutic approaches?Date/Time:Thursday, June 6, 2024 (5:00 to 5:15 p.m. BST)Presenter:Jennifer L. Taylor-Cousar, M.D., National Jewish Health The presentation from the 47th European Cystic Fibrosis Conference will also be available on the 4DMT website: https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications Corporate Webcast Details: Title:4D-710 Phase 1/2 AEROW Interim Clinical Data & Program UpdateDate/Time:Thursday, June 6, 2024 at 8:00 a.m. ETRegistration:Link An archived copy of the webcast will be available for up to one year by visiting the “Investors & Media” section of the 4DMT website at the following link: https://ir.4dmoleculartherapeutics.com/events. About Cystic Fibrosis Lung Disease Cystic fibrosis (CF) is an inherited progressive disease caused by mutations in the CFTR gene. It affects the lungs, pancreas and other organs. According to the Cystic Fibrosis Foundation, nearly 40,000 people in the United States and more than 105,000 people worldwide are living with CF, with approximately 1,000 new cases of CF diagnosed in the United States each year. Lung disease is the leading cause of morbidity and mortality in people with CF....